# How Teva Pharmaceutical Industries (TEVA) compares with the whole market and its popular alternatives

> Source: EasyCompare research, https://easycompare.io/research/teva
> Data as of October 20, 2026. Total returns include reinvested dividends. Past performance does not predict future results; nothing here is investment advice.

Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on TEVA alone. It places TEVA (Teva Pharmaceutical Industries Limited) against 19 popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where TEVA stands in the market, and of the alternatives worth a closer look.

Period covered: TEVA's full trading record, from October 1986 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.

## Key findings

- **Right now:** TEVA has run far ahead of the market, rising 31.8% over the past 3 months against 3.9% for the S&P 500 and 3.2% for the Nasdaq 100. On the flip side, the slide is TEVA's own: it is 39.0% below its high, against 1.3% for the S&P 500.
- **Stock or market?:** TEVA's 31.8% gain over the past 3 months far outran its industry: the pharmaceuticals ETF IHE (iShares U.S. Pharmaceuticals ETF) rose 5.0%. The S&P 500 rose 3.9%. Its pharmaceutical peers did not move as one over the past 3 months: PRGO (Perrigo) rose 55.8%, while SNY (Sanofi) fell 5.9%.
- **Past 1 to 3 years:** Over the past year, TEVA rose 110% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (403% against 89.3%). A behind 84% of stocks worth at least $300 million over 10 years, but ahead of 95% of the stocks worth at least $300 million over 3 years.
- **Long term:** TEVA turned $10,000 into $9,640 over the past decade, against $42,100 in the S&P 500. That said, the past 5 years have been the better stretch: TEVA rose 303% against 81.7% for the S&P 500, after trailing over the decade.
- **In a crash:** Across seven sell-offs, TEVA has typically fallen 1.3 times as far as the S&P 500.
- **Diversification:** Against the S&P 500, TEVA has a correlation of 0.35 over 5 years, less closely than 60% of stocks worth at least $300 million. Next to an index fund it is some diversification, but not a hedge. Over 10 years, TEVA's beta versus the S&P 500 was 1.11: in the S&P 500's rising months it gained 55% as much as the index, and in falling months it lost 1.2 times as much.
- **Better options**
  - **Popular alternatives:** CAH (Cardinal Health) and MCK (McKesson) earned more than TEVA with less volatility over the past 5 years. CAH returned 42.1% a year at 24.7% volatility, against 32.2% a year at 42.8%.
  - **Nearby categories and themes:** LLY (Eli Lilly and Company, pharmaceuticals) earned more than TEVA with less volatility over the past 5 years: 40.7% a year at 32.8% volatility, against 32.2% a year at 42.8%.
  - **Whole market:** Few investments have done better on both counts: only 37 of the 3,633 stocks and funds worth at least $500 million earned more than TEVA with less volatility over the past 5 years, among them LLY (Eli Lilly and Company), GE (GE Aerospace) and MUFG (Mitsubishi UFJ Financial Group).

## How much would $10,000 in TEVA have grown?

This chart tracks a hypothetical $10,000 investment in TEVA over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of TEVA over the same span and TEVA's popular alternatives, among those that traded for the entire period.

- $10,000 invested in TEVA at the end of September 1997 would have grown to $76,156 by September 2026, less than the $132,907 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of TEVA, and COR finished highest, at $574,137.

## TEVA at a glance

This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout.

- TEVA is still 39.0% below its all-time high.
- TEVA's deepest decline since it began trading in 1986 was 90.8%, from July 2015 to August 2019. It has not yet climbed back to that peak.
- Over 29 full calendar years, TEVA's best was 2024, when it returned 111%, and its worst was 2017, when it lost 45.9%. It lost money in 14 of those years.

- Type: Stock, Healthcare (Drug Manufacturers - Specialty & Generic)
- Trading since: October 17, 1986
- Market value: $48B
- Volatility (5 years): 42.8%; Sharpe ratio: 0.86
- Worst decline ever: −90.8%, from July 27, 2015 to August 15, 2019; not yet back at its high

| Period | TEVA total return |
| --- | --- |
| 1 month | +2.0% |
| 3 months | +31.8% |
| 6 months | +27.6% |
| year to date | +32.0% |
| 1 year | +110% |
| 3 years | +403% |
| 5 years | +303% |
| 10 years | −3.6% |

## TEVA against the whole market

Where TEVA ranks among every stock and fund, and what across the market has done better.

### How does TEVA rank among all stocks?

This section ranks TEVA on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history.

- TEVA's 1-year return ranks in the top 4% of the 3,287 stocks worth at least $300 million with 1 year of history.
- TEVA's 10-year return ranks in the bottom 16% of the 2,202 stocks worth at least $300 million with 10 years of history.

| Measure | TEVA | Rank |
| --- | --- | --- |
| 1-year return | +110% | 146 of 3,287 (top 5%) |
| 3-year return | +403% | 145 of 3,017 (top 5%) |
| 5-year return | +303% | 166 of 2,893 (top 6%) |
| 10-year return | −3.6% | 1,841 of 2,202 (top 84%) |
| Volatility, 5 years | 42.8% | 1,598 of 2,893 (top 56%) |
| Sharpe ratio, 5 years | 0.86 | 215 of 2,893 (top 8%) |
| Worst decline, past 10 years | −85.5% | 1,800 of 2,187 (top 83%) |

### What has beaten TEVA on both return and risk?

Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer).

- 36 stocks and one ETF worth at least $500 million sit in the green region: each earned more than TEVA over the past 5 years with smaller price swings. That is 1% of the 3,633 screened. Few investments beat it on both counts.
- Among those with at least half TEVA's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 42% less than TEVA's 42.8%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 0.86 for TEVA. INSW earned the most, 56.5% a year, while still swinging less than TEVA (40.5% against 42.8%).
- Among TEVA's popular alternatives, CAH and MCK are in the region. CAH earned 42.1% a year against 32.2% a year for TEVA, at 24.7% volatility, 42% less than TEVA's 42.8%.

### Is there a better investment than TEVA?

The table below lists investments that beat TEVA over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes.

- Among TEVA's popular alternatives, CAH and MCK earned more than TEVA with less volatility over the past 5 years. CAH returned 42.1% a year at 24.7% volatility, against 32.2% a year at 42.8%.
- Looking beyond its popular alternatives, LLY (pharmaceuticals) earned more than TEVA with less volatility over the past 5 years: 40.7% a year at 32.8% volatility, against 32.2% a year at 42.8%.
- Few investments have done better on both counts: only 37 of the 3,633 stocks and funds worth at least $500 million earned more than TEVA with less volatility over the past 5 years, among them LLY, GE and MUFG.

The 15 strongest of 37 investments that beat TEVA over the past 5 years, out of 3,633 stocks and funds worth at least $500 million.

| Investment | Group | Annual return (5 years) | Volatility | Sharpe | Worst decline (10 years) | 10Y return | Correlation with TEVA | Better on |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| TEVA: Teva Pharmaceutical Industries Limited (this page) |  | +32.2% | 42.8% | 0.86 | −85.5% | −3.6% |  |  |
| [MPC](https://easycompare.io/research/mpc): Marathon Petroleum Corporation | Oil & Gas | +51.2% | 33.4% | 1.41 | −79.7% | +1,387% | 0.13 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [PBR-A](https://easycompare.io/research/pbr-a): Petróleo Brasileiro S.A. - Petrobras | Integrated Oil & Gas | +51.8% | 37.5% | 1.31 | −71.7% | +768% | 0.19 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [PBR](https://easycompare.io/research/pbr): Petróleo Brasileiro S.A. - Petrobras | Integrated Oil & Gas | +50.3% | 37.5% | 1.28 | −75.3% | +674% | 0.13 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [VLO](https://easycompare.io/research/vlo): Valero Energy Corporation | Oil & Gas | +44.2% | 36.9% | 1.18 | −71.9% | +1,061% | 0.17 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [PSX](https://easycompare.io/research/psx): Phillips 66 | Oil & Gas | +33.2% | 32.9% | 1.04 | −64.2% | +430% | 0.16 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [CAH](https://easycompare.io/research/cah): Cardinal Health, Inc. | Health Care Distribution | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.06 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| [APH](https://easycompare.io/research/aph): Amphenol Corporation | Electronic Components | +33.8% | 32.2% | 1.07 | −37.5% | +965% | 0.29 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| DHT: DHT Holdings, Inc. | Marine Shipping | +38.7% | 39.0% | 1.04 | −39.7% | +1,050% | 0.02 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Higher return in most periods |
| [LLY](https://easycompare.io/research/lly): Eli Lilly and Company | Pharmaceuticals | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.12 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| ESLT: Elbit Systems Ltd. | Aerospace & Defense | +39.8% | 34.6% | 1.15 | −35.4% | +765% | -0.08 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| EME: EMCOR Group, Inc. | Engineering & Construction | +43.0% | 35.3% | 1.20 | −48.0% | +1,202% | 0.14 | Higher return, lower volatility; Higher Sharpe, smaller worst decline; Smaller losses in recent crashes |
| [HWM](https://easycompare.io/research/hwm): Howmet Aerospace Inc. | Aerospace & Defense | +47.3% | 32.5% | 1.36 | −68.9% | +1,028% | 0.21 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| [MUFG](https://easycompare.io/research/mufg): Mitsubishi UFJ Financial Group, Inc. | Banks | +33.2% | 29.4% | 1.13 | −54.9% | +483% | 0.30 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| INSW: International Seaways, Inc. | Oil & Gas | +56.5% | 40.5% | 1.31 | −57.4% | — | 0.14 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| [BBVA](https://easycompare.io/research/bbva): Banco Bilbao Vizcaya Argentaria, S.A. | Banks | +38.7% | 33.3% | 1.16 | −69.6% | +542% | 0.30 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |

## TEVA against its popular alternatives

The investments people most often weigh against TEVA, compared period by period and year by year.

### How do TEVA's risk and return compare with its alternatives?

This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings.

- Only CAH and MCK were both more rewarding and calmer than TEVA over the past 5 years, earning a higher annual return with lower volatility.
- Over the past 5 years, TEVA returned 32.2% a year, more than the S&P 500's 12.7%, with higher volatility (42.8% against 17.1%).

### Has TEVA consistently beaten its popular alternatives?

This section compares TEVA with the investments people most often weigh against it, checking each one over eight periods from one month to ten years.

- None of the 19 popular alternatives outperformed TEVA in at least 3 of 5 short-term and 2 of 3 long-term timeframes. The closest was MCK.
- CAH, MCK and COR earned more for the risk they took than TEVA (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.

| Investment | 1Y return | 3Y return | 5Y return | 10Y return | Periods ahead of TEVA | Verdict | Sharpe |
| --- | --- | --- | --- | --- | --- | --- | --- |
| TEVA: Teva Pharmaceutical Industries Limited (this page) | +110% | +403% | +303% | −3.6% |  |  | 0.86 |
| [MCK](https://easycompare.io/research/mck): McKesson Corporation | +31.3% | +131% | +413% | +586% | 1/5 short-term, 2/3 long-term |  | 1.44 |
| [CAH](https://easycompare.io/research/cah): Cardinal Health, Inc. | +65.3% | +191% | +479% | +349% | 1/5 short-term, 2/3 long-term |  | 1.55 |
| PCRX: Pacira BioSciences, Inc. | +58.0% | +27.6% | −31.5% | +9.2% | 4/5 short-term, 1/3 long-term |  | 0.11 |
| AMRX: Amneal Pharmaceuticals, Inc. | +93.8% | +472% | +247% | −9.4% | 2/5 short-term, 1/3 long-term |  | 0.74 |
| [COR](https://easycompare.io/research/cor): Cencora, Inc. | +5.7% | +86.5% | +195% | +406% | 1/5 short-term, 1/3 long-term |  | 1.07 |
| [NVS](https://easycompare.io/research/nvs): Novartis AG | +18.8% | +75.9% | +121% | +226% | 1/5 short-term, 1/3 long-term |  | 0.87 |
| RDY: Dr. Reddy's Laboratories Limited | −9.2% | +2.3% | +9.0% | +59.4% | 1/5 short-term, 1/3 long-term |  | 0.19 |
| [PFE](https://easycompare.io/research/pfe): Pfizer Inc. | +30.5% | +19.2% | −8.3% | +55.0% | 1/5 short-term, 1/3 long-term |  | 0.06 |
| [CVS](https://easycompare.io/research/cvs): CVS Health Corp. | +18.5% | +52.5% | +29.2% | +47.0% | 1/5 short-term, 1/3 long-term |  | 0.32 |
| SUPN: Supernus Pharmaceuticals, Inc. | −20.1% | +69.6% | +37.9% | +97.5% | 0/5 short-term, 1/3 long-term |  | 0.36 |
| JAZZ: Jazz Pharmaceuticals plc | +58.5% | +60.1% | +46.7% | +75.8% | 0/5 short-term, 1/3 long-term |  | 0.40 |
| [SNY](https://easycompare.io/research/sny): Sanofi | −13.4% | −10.0% | +3.0% | +61.5% | 0/5 short-term, 1/3 long-term |  | 0.15 |
| COLL: Collegium Pharmaceutical, Inc. | −33.3% | +8.2% | +9.7% | +29.9% | 0/5 short-term, 1/3 long-term |  | 0.25 |
| ANIP: ANI Pharmaceuticals, Inc. | −23.6% | +26.5% | +91.9% | +8.8% | 0/5 short-term, 1/3 long-term |  | 0.50 |
| MNKD: MannKind Corporation | −43.5% | −26.4% | −27.9% | +1.6% | 0/5 short-term, 1/3 long-term |  | 0.19 |
| PRGO: Perrigo Company plc | −18.4% | −35.6% | −55.5% | −75.3% | 3/5 short-term, 0/3 long-term |  | -0.23 |
| VTRS: Viatris Inc. | +87.1% | +127% | +64.3% | −38.0% | 2/5 short-term, 0/3 long-term |  | 0.47 |
| HRMY: Harmony Biosciences Holdings, Inc. | +48.7% | +92.3% | −7.8% | — | 1/5 short-term, 0/3 long-term |  | 0.22 |
| ALK: Alaska Air Group, Inc. | −29.2% | +7.3% | −40.0% | −51.2% | 0/5 short-term, 0/3 long-term |  | -0.02 |

### How did TEVA do year by year?

This table shows each investment's total return in every full calendar year since 1997, along with where TEVA ranked among its popular alternatives each year.

- TEVA finished ahead of the S&P 500 in 13 of its 29 full calendar years, and ahead of it in each of the last two.
- Among its popular alternatives, COLL came out ahead of TEVA most often, in seven of the ten years both traded.
- Ranked against its popular alternatives each year, TEVA finished in the top quarter in ten of 29 years and in the bottom quarter in ten. In 2025, it ranked 9 of 20.

| Year | TEVA | SPY |
| --- | --- | --- |
| 2025 | +41.6% | +17.7% |
| 2024 | +111% | +24.9% |
| 2023 | +14.5% | +26.2% |
| 2022 | +13.9% | −18.2% |
| 2021 | −17.0% | +28.7% |
| 2020 | −1.5% | +18.3% |
| 2019 | −36.4% | +31.2% |
| 2018 | −18.6% | −4.6% |
| 2017 | −46.0% | +21.7% |
| 2016 | −43.2% | +12.0% |

## Risk and diversification

How TEVA has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.

### What were TEVA's worst declines?

A drawdown is the decline from a peak to the lowest point before a new high.

- In all four of TEVA's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: TEVA fell 90.8% from July 2015 to August 2019, while the S&P 500 rose 49.1%.
- The slowest recovery came after TEVA fell 44.0% from March 2010 to September 2011; it did not regain that peak until November 2014, three years later.

| Decline | Peak | Low | Back at the high | SPY over the same dates | Market event |
| --- | --- | --- | --- | --- | --- |
| −90.8% | July 27, 2015 | August 15, 2019 | not yet | +49.1% | 2015 China and oil sell-off |
| −60.0% | June 10, 1987 | February 4, 1988 | November 17, 1989 | — |  |
| −52.0% | June 20, 1997 | July 10, 1998 | December 29, 1999 | +31.8% |  |
| −44.0% | March 23, 2010 | September 23, 2011 | November 4, 2014 | −0.4% | 2011 euro debt crisis |
| −36.9% | February 24, 1994 | January 10, 1995 | April 13, 1995 | +1.7% |  |

### How did TEVA do in stock market crashes?

This section measures how far TEVA, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000.

- TEVA fell further than the S&P 500 in eight of the ten crashes it has traded through. The clearest case was the late-2018 sell-off, when TEVA fell 40.1% and the S&P 500 fell 19.3%.
- Among its popular alternatives, CAH held up best, falling less than TEVA in eight of the ten crashes they both traded through.

| Crash | Dates | TEVA fall | SPY fall |
| --- | --- | --- | --- |
| Dot-com bust | March 10, 2000 to October 9, 2002 | −34.7% | −47.5% |
| Global financial crisis | October 9, 2007 to March 9, 2009 | −23.5% | −55.2% |
| Flash crash | May 6, 2010 to May 7, 2010 | −2.4% | −1.5% |
| Euro debt crisis | July 22, 2011 to October 3, 2011 | −25.8% | −17.9% |
| China devaluation & oil rout | August 10, 2015 to February 11, 2016 | −21.8% | −12.8% |
| Volmageddon | February 2, 2018 to February 9, 2018 | −10.7% | −6.5% |
| Q4 2018 selloff | September 21, 2018 to December 24, 2018 | −40.1% | −19.3% |
| COVID crash | February 19, 2020 to March 23, 2020 | −50.3% | −33.7% |
| 2022 bear market | January 4, 2022 to October 12, 2022 | −34.0% | −24.5% |
| SVB / regional bank stress | March 8, 2023 to March 13, 2023 | −7.4% | −3.4% |

### How closely does TEVA move with the S&P 500?

Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell.

- 14 of the 18 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than TEVA's 0.48, led by MCK, CAH and COR.
- MCK took just 27% of the S&P 500's losses, against 116% for TEVA, while still keeping 72% of its gains.
- Over the past 10 years, TEVA captured 55% of the S&P 500's gains in rising months and 116% of its losses in falling months, with a beta of 1.11. Its share of the market's losses was larger than its share of the gains.

Measured over the past 10 years of monthly returns against SPY.

| Investment | Upside capture | Downside capture | Beta |
| --- | --- | --- | --- |
| TEVA: Teva Pharmaceutical Industries Limited (this page) | 55.0% | 116% | 1.11 |
| [MCK](https://easycompare.io/research/mck): McKesson Corporation | 72.0% | 27.0% | 0.56 |
| [CAH](https://easycompare.io/research/cah): Cardinal Health, Inc. | 71.0% | 51.0% | 0.75 |
| PCRX: Pacira BioSciences, Inc. | 25.0% | 71.0% | 0.64 |
| AMRX: Amneal Pharmaceuticals, Inc. | 93.0% | 189% | 1.20 |
| [COR](https://easycompare.io/research/cor): Cencora, Inc. | 80.0% | 58.0% | 0.56 |
| [NVS](https://easycompare.io/research/nvs): Novartis AG | 69.0% | 64.0% | 0.49 |
| RDY: Dr. Reddy's Laboratories Limited | 27.0% | 26.0% | 0.38 |
| [PFE](https://easycompare.io/research/pfe): Pfizer Inc. | 52.0% | 81.0% | 0.54 |
| [CVS](https://easycompare.io/research/cvs): CVS Health Corp. | 59.0% | 99.0% | 0.70 |
| SUPN: Supernus Pharmaceuticals, Inc. | 78.0% | 115% | 0.87 |
| JAZZ: Jazz Pharmaceuticals plc | 62.0% | 78.0% | 0.64 |
| [SNY](https://easycompare.io/research/sny): Sanofi | 53.0% | 74.0% | 0.46 |
| COLL: Collegium Pharmaceutical, Inc. | 58.0% | 106% | 0.89 |
| ANIP: ANI Pharmaceuticals, Inc. | 54.0% | 101% | 0.82 |
| MNKD: MannKind Corporation | 121% | 216% | 1.50 |
| PRGO: Perrigo Company plc | 22.0% | 147% | 0.87 |
| VTRS: Viatris Inc. | 74.0% | 179% | 1.14 |
| ALK: Alaska Air Group, Inc. | 80.0% | 186% | 1.51 |

### What diversifies TEVA?

Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions).

- Moving a fifth of the money in TEVA into MCK would have cut the portfolio's volatility by 19% over the past 5 years and raised its annual return (+32.4% for TEVA alone, +35.0% for the mix).
- MCK made money in ten of the 14 calendar years in which TEVA lost money.
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of TEVA over the past 5 years, with correlations of 0.38 or lower, and each still earned a positive 5-year return.

| Investment | Correlation with TEVA | 5Y return | Volatility | Sharpe | Rose in TEVA's 14 down years |
| --- | --- | --- | --- | --- | --- |
| LVHI: Franklin International Low Volatility High Dividend Index ETF | 0.37 | +119% | 11.1% | 1.48 | 3 of 14 |
| DXJ: WisdomTree Japan Hedged Equity Fund | 0.38 | +225% | 19.1% | 1.34 | 6 of 14 |
| EMLP: First Trust North American Energy Infrastructure Fund | 0.18 | +101% | 14.5% | 1.04 | 4 of 14 |
| HDV: iShares Core High Dividend ETF | 0.27 | +83.3% | 13.0% | 1.00 | 5 of 14 |
| [SMH](https://easycompare.io/research/smh): VanEck Semiconductor ETF | 0.28 | +323% | 36.9% | 0.97 | 8 of 14 |
| DBEF: Xtrackers MSCI EAFE Hedged Equity ETF | 0.36 | +85.0% | 13.8% | 0.96 | 6 of 14 |
| [GLD](https://easycompare.io/research/gld): SPDR Gold Shares | 0.05 | +126% | 18.9% | 0.96 | 9 of 14 |
| SPMO: Invesco S&P 500 Momentum ETF | 0.32 | +136% | 20.8% | 0.93 | 5 of 14 |

## Common questions

### What was TEVA's worst drawdown?

TEVA's deepest decline since it began trading in 1986 was 90.8%, from July 2015 to August 2019. It has not yet climbed back to that peak.

### What were TEVA's best and worst years?

Over 29 full calendar years, TEVA's best year was 2024, when it returned 111%. Its worst was 2017, with a return of -45.9%.

### Is there a better investment than TEVA?

Among TEVA's popular alternatives, CAH and MCK earned more than TEVA with less volatility over the past 5 years. CAH returned 42.1% a year at 24.7% volatility, against 32.2% a year at 42.8%. Looking beyond its popular alternatives, LLY (pharmaceuticals) earned more than TEVA with less volatility over the past 5 years: 40.7% a year at 32.8% volatility, against 32.2% a year at 42.8%.

### Is TEVA more volatile than the S&P 500?

Yes. TEVA's volatility over the past 5 years was 42.8%, 2.5 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, TEVA's return lands within 42.8% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.

### What is TEVA's Sharpe ratio?

TEVA's Sharpe ratio over the past 5 years was 0.86, against 0.79 for the S&P 500, so TEVA earned more for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.

### How correlated is TEVA with the S&P 500?

Over the past 5 years, TEVA's monthly returns had a correlation of 0.35 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are only loosely linked, which makes it a real diversifier next to an index fund. In the table, the correlation column measures each option against TEVA instead: the lower it is, the more that option would diversify a TEVA holding.

### What are the best alternatives to TEVA?

None of the 19 popular alternatives we compared outperformed TEVA in at least 3 of 5 short-term and 2 of 3 long-term timeframes, which says more about TEVA's strength than about its alternatives.

### Did TEVA outperform the S&P 500?

TEVA finished ahead of the S&P 500 (SPY) in 13 of 29 full calendar years. In 2025, it returned +41.6%, against +17.7% for the index.

### How did TEVA do in stock market crashes?

TEVA fell less than the S&P 500 (SPY) in two of the ten major crashes it has traded through, and further in eight. The clearest case was the late-2018 sell-off, when TEVA fell 40.1% and the S&P 500 fell 19.3%.

### What diversifies TEVA?

These had a low correlation with TEVA over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.37), DXJ (correlation 0.38) and EMLP (correlation 0.18); among large stocks, CAH (correlation 0.06), CLS (correlation 0.21) and FIX (correlation 0.11). A correlation near zero means the two have moved largely independently.

## More research

- [McKesson (MCK) Performance, Alternatives and Market Rank](https://easycompare.io/research/mck)
- [Cardinal Health (CAH) Performance, Alternatives and Market Rank](https://easycompare.io/research/cah)
- [Cencora (COR) Performance, Alternatives and Market Rank](https://easycompare.io/research/cor)
- [Novartis (NVS) Performance, Alternatives and Market Rank](https://easycompare.io/research/nvs)
- [Pfizer (PFE) Performance, Alternatives and Market Rank](https://easycompare.io/research/pfe)
- [CVS Health (CVS) Performance, Alternatives and Market Rank](https://easycompare.io/research/cvs)
- [Sanofi (SNY) Performance, Alternatives and Market Rank](https://easycompare.io/research/sny)
- [Schwab U.S. Dividend Equity ETF (SCHD) Performance, Alternatives and Market Rank](https://easycompare.io/research/schd)
- [NVIDIA (NVDA) Performance, Alternatives and Market Rank](https://easycompare.io/research/nvda)
- [Apple (AAPL) Performance, Alternatives and Market Rank](https://easycompare.io/research/aapl)
- [Alphabet (GOOG) Performance, Alternatives and Market Rank](https://easycompare.io/research/goog)
- [Microsoft (MSFT) Performance, Alternatives and Market Rank](https://easycompare.io/research/msft)

## Explore further

- Full page with charts: https://easycompare.io/research/teva
- All research pages: https://easycompare.io/llms.txt
- Compare the entire market against TEVA live: https://betterthanspy.com/?b=TEVA&utm_source=easycompare&utm_medium=research